Overall, if confirmed by separate prospective studies, these results suggest that serum CCL18 could be used in clinical management as a marker of progressive ILD, to aid in targeting treatment to the correct patients, and should be evaluated as a potential therapeutic target. This evidence concerns the gene CCL18 and interstitial lung disease.